Clinical effects of lyophilize recombinant human brain natriuretie peptide on refractory heart failure
Zhang Qi
Zhang Weijuan
Meng Jianjiang
Abstract：Objective To investigate the clinical effects of lyophilized recombinant human brain natriuretic peptide on refractory heart failure.Methods Totally 31 cases of refractory heart failure patients were treated with lyophilized recombinant human brain natriuretic peptide.The first loading dose of 1.5 μg/kg was intravenous in 3-5 min,followed by a maintenance dose of 0.007 5-0.01/(kg · min) conduct micro pump injection of at least 72 h.Symptom of breath,24 h urine output,heart rate,left ventricular ejection fraction (LVEF) and N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels was evaluated and measured before and after treatment.Results After 24 hours of recombinant human brain natriuretic peptide therapy,total response rate of dyspnea grade improvement was 90.3％ (28/31).NT-proBNP one week after treatment was decreased slightly compared with before treatment[(5 042 ± 1 123) ng/L vs (6 020 ± 1 130) ng/L] (P ＜ 0.05) ; LVEF values increased [(47±15)％ vs (41 ±15)％] (P＜0.05); urine output increased[(1 911 ±892)ml vs (1 326±802)ml] (P ＜0.05).Conclusion The recombinant human brain natriuretic peptide can significantly improve cardiac function and clinical symptoms in patients with refractory heart failure.
Keywords：Recombinant human brain natriuretic peptideRefractoryHeart failure
Publication Date：2014-06-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 799-801 )